From the CEO update 9 July 2018 ...
On 1 June 2018 we held the first formal review of our platform with our newly appointed Scientific Advisory Board. It was clear from this discussion that Phylogica has a near-term opportunity to improve the commercial attractiveness of our platform by showing that we can deliver a cargo class of interest into a target cell of interest more efficiently than the relevant competitive technology.
This sounds to me like the Advisory Board saying “you are on the right path so demonstrate it, build your data pack and get ahead of your competition.
My initial thoughts were that they have dumped a tough target (MYC) to tackle a tougher target. However, I now understand and accept the reasoning behind the MYC decision and I sense that the next step (demonstrate it) will be a massive moment for the company. Gee I hope so.
- Forums
- ASX - By Stock
- PYC
- Ann: AGM Company Presentation
Ann: AGM Company Presentation, page-36
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M |
Open | High | Low | Value | Volume |
18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 118941 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 183634 | 2 |
Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online